144 related articles for article (PubMed ID: 9838331)
1. Changes in serum lipid and (APO) lipoprotein levels in renal transplant recipients.
Ishii T; Imanishi M; Nishioka T; Kunikata S; Akiyama T; Kurita T
Transplant Proc; 1998 Nov; 30(7):3021-2. PubMed ID: 9838331
[No Abstract] [Full Text] [Related]
2. Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia.
Saku K; Sasaki J; Arakawa K
Clin Ther; 1989; 11(2):247-57. PubMed ID: 2736571
[TBL] [Abstract][Full Text] [Related]
3. Effects of hormone replacement therapy and hepatic lipase polymorphism on serum lipid profiles in postmenopausal Japanese women.
Somekawa Y; Umeki H; Kobayashi K; Tomura S; Aso T; Hamaguchi H
J Clin Endocrinol Metab; 2002 Oct; 87(10):4766-70. PubMed ID: 12364471
[TBL] [Abstract][Full Text] [Related]
4. Serum lipoproteins in renal transplant patients: the effect of cyclosporine on lipoprotein(a).
Süleymanlar G; Ozben T; Sapan M; Yìlmaz H; Yakupoglu G; Karpuzoglu T
Transplant Proc; 1994 Oct; 26(5):2637-8. PubMed ID: 7940822
[No Abstract] [Full Text] [Related]
5. Factors influencing plasma lipid profiles including lipoprotein (a) concentrations in renal transplant recipients.
Wheeler DC; Morgan R; Thomas DM; Seed M; Rees A; Moore RH
Transpl Int; 1996; 9(3):221-6. PubMed ID: 8723190
[TBL] [Abstract][Full Text] [Related]
6. Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein (a) in patients with non-insulin dependent diabetes mellitus.
Umeda F; Watanabe J; Inoue K; Hisatomi A; Mimura K; Yamauchi T; Sako Y; Kunisaki M; Tajiri Y; Nawata H
Endocrinol Jpn; 1992 Feb; 39(1):45-50. PubMed ID: 1535040
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein and lipid abnormalities in uremic children on hemodialysis.
Ohta T; Matsuda I
Clin Chim Acta; 1985 Apr; 147(2):145-54. PubMed ID: 3921292
[TBL] [Abstract][Full Text] [Related]
8. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients.
Nishizawa Y; Shoji T; Emoto M; Kawasaki K; Konishi T; Tabata T; Inoue T; Morii H
Clin Nephrol; 1995 Apr; 43(4):268-77. PubMed ID: 7606882
[TBL] [Abstract][Full Text] [Related]
9. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
[TBL] [Abstract][Full Text] [Related]
10. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
Saku K; Sasaki J; Arakawa K
Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
[TBL] [Abstract][Full Text] [Related]
11. Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.
Schulzeck P; Bojanovski M; Jochim A; Canzler H; Bojanovski D
Lancet; 1988 Mar; 1(8586):611-3. PubMed ID: 2894548
[TBL] [Abstract][Full Text] [Related]
12. [Serum lipids and apolipoproteins AI, B100, CI and CII in patients with apoplexy].
Liu BW; Zhang ZH; Wu ZF; Fu MD; Zhang RJ; Fan P; Zhang P; Hu CH; Luo ZM; She LM
Hua Xi Yi Ke Da Xue Xue Bao; 1989 Mar; 20(1):9-12. PubMed ID: 2507441
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein heterogeneity at birth: influence of gestational age and race on lipoprotein subclasses and Lp (a) lipoprotein.
Kwiterovich PO; Virgil DG; Garrett ES; Otvos J; Driggers R; Blakemore K; Cockrill SL; Macfarlane RD
Ethn Dis; 2004; 14(3):351-9. PubMed ID: 15328936
[TBL] [Abstract][Full Text] [Related]
14. Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia.
Matsunaga A; Handa K; Mori T; Moriyama K; Hidaka K; Yuki M; Sasaki J; Arakawa K
Atherosclerosis; 1992 Jun; 94(2-3):241-8. PubMed ID: 1385959
[TBL] [Abstract][Full Text] [Related]
15. Effects of cerivastatin on lipid profiles, lipid peroxidation and platelet and endothelial activation in renal transplant recipients.
Caillard S; Leray C; Kunz K; Gachet C; Offner M; Wiesel ML; Hannedouchte T; Cazenave JP; Moulin B
Transplant Proc; 2000 Dec; 32(8):2787-8. PubMed ID: 11134806
[No Abstract] [Full Text] [Related]
16. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
Ginsberg HN; Le NA; Goldberg IJ; Gibson JC; Rubinstein A; Wang-Iverson P; Norum R; Brown WV
J Clin Invest; 1986 Nov; 78(5):1287-95. PubMed ID: 3095375
[TBL] [Abstract][Full Text] [Related]
17. Hyperlipidaemia and post-heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporin A.
Massy ZA; De Bandt JP; Morelon E; Thevenin M; Lacour B; Kreis H
Nephrol Dial Transplant; 2000 Jun; 15(6):928. PubMed ID: 10831671
[No Abstract] [Full Text] [Related]
18. Hyperlipidemia in stable renal transplant recipients.
Ong-Ajyooth L; Sirisalee K; Shayakul C; Vareesangthip K; Vasuvattakul S; Chirawong P; Vanichakarn S; Nimmannit S; Ong-Ajyooth S; Nilwarangkur S
Transplant Proc; 1994 Aug; 26(4):2062-4. PubMed ID: 8066670
[No Abstract] [Full Text] [Related]
19. Serum apolipoprotein A-I levels: relationship to lipoprotein lipid levels and selected demographic variables.
Phillips NR; Havel RJ; Kane JP
Am J Epidemiol; 1982 Aug; 116(2):302-13. PubMed ID: 6810694
[TBL] [Abstract][Full Text] [Related]
20. Studies on the mechanism of hypertriglyceridemia in Tangier disease. Determination of plasma lipolytic activities, k1 values and apolipoprotein composition of the major lipoprotein density classes.
Wang CS; Alaupovic P; Gregg RE; Brewer HB
Biochim Biophys Acta; 1987 Jul; 920(1):9-19. PubMed ID: 3109493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
